Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod.
An official website of the United States government
A .gov website belongs to an official government organization in the United States.
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
July 27, 2022
The COVID-19 pandemic is rapidly evolving, and new updates are issued frequently. To view a full list of HHS/ASPR’s updates related to COVID-19 monoclonal antibody therapeutics, please see our full list of updates.
HHS/ASPR has partnered with AstraZeneca to establish an additional pathway for providers to access the COVID-19 drug Evusheld for use with eligible patients. Individual providers and smaller sites of care that do not currently receive Evusheld through the HHS Health Partner Order Portal (or HPOP) distribution process can now order small, limited quantities of product (1-3 patient courses).
Evusheld is a medicine used in adults and children ages 12 years and older. It offers an extra layer of protection on top of vaccination for individuals who are moderately or severely immunocompromised and can offer protection for those who are severely allergic to COVID-19 vaccines. Evusheld consists of two monoclonal antibodies provided together to help prevent infection with the virus that causes COVID-19. A healthcare provider gives Evusheld as two separate, consecutive intramuscular injections at a doctor’s office or healthcare facility.
Additional information about Evusheld, including patient eligibility and how to find an administration site, can be found on ASPR’s website.
AstraZeneca has established a helpline to receive additional general product information as well as specific guidance on how to access the product, including information on ordering.
